
Clotting factors: the AstraZeneca vaccine
The Intelligence from The Economist
Intro
This chapter examines recent analysis by European and British regulators regarding the potential link between blood clots and the AstraZeneca-Oxford COVID vaccine. It discusses the implications of these findings, the cautious stance of health authorities, and the effects on public perception and vaccine rollout.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.